C-3.18.3. Duplicative Therapy

Adjunctive administration of multiple exogenous insulin products may be required or recommended to maintain adequate glycemic control. If multiple exogenous insulin products are required or recommended, the patients generally have one long-acting or intermediate-acting basal insulin product and one short- or rapid-acting preprandial insulin product 1-38. Patient profiles containing prescriptions for multiple short-acting or multiple long-acting exogenous insulin products will be reviewed.